BBP-812

About BridgeBio Pharma

BridgeBio Pharma is a clinical-stage biotech with a mission to translate genetic insights into life-changing medicines for rare diseases and cancers. The company has achieved significant milestones, including three FDA approvals, a robust late-stage pipeline with six Phase 3 trials conducted, and a market valuation reflecting strong investor confidence. Its core strategy leverages a decentralized hub-and-spoke operational model to pursue multiple high-precision programs simultaneously, targeting conditions with clear genetic etiology and significant unmet need.

Therapeutic Areas

Other Canavan Disease Drugs